SEC-sourced researchBeta
ATXI
AVENUE THERAPEUTICS, INC.
Company comparison ↗
Data passport
- CIK
- 0001644963
- Exchange
- OTC
- Business activity
- Pharmaceutical Preparations · SIC 2834
- Financial inputs
- 6/6
- Filing date
- Nov 6, 2026
- SEC registry record
- Operating company
Annual financial history
Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.
| Period end | Revenue | Filing date |
|---|---|---|
| December 2024 | 0.0000 | Mar 30, 2026 |
| December 2025 | 1,404,000.0000 | Mar 30, 2026 |
Annual periods · USD
| Period end | Revenue | Net income | Operating cash flow | Total assets | Total liabilities | Filing date |
|---|---|---|---|---|---|---|
| December 2025 | 1,404,000.0000 | -2,909,000.0000 | -1,833,000.0000 | 2,931,000.0000 | 1,099,000.0000 | Mar 30, 2026 |
| December 2024 | 0.0000 | -11,652,000.0000 | -9,026,000.0000 | 2,672,000.0000 | 816,000.0000 | Mar 30, 2026 |
Explainable fundamental score
Five equally weighted components based on SEC financial inputs. No price inputs or personal investment preferences.
43/100
Profitability0
Growth—
Balance sheet63
Cash generation0
Data coverage100
Component weight: 20% · Minimum data coverage: 50% · Missing component value: 50/100
Financial inputs behind the calculation
| Financial inputs | USD | Period end | Filing date | Form |
|---|---|---|---|---|
| RevenueRevenues | $1.4M | Jan 1, 2025 – Dec 31, 2025 | Mar 30, 2026 | 10-K |
| Previous period revenueRevenues | $0 | Jan 1, 2024 – Dec 31, 2024 | Mar 30, 2026 | 10-K |
| Net incomeNetIncomeLoss | -$2.91M | Jan 1, 2025 – Dec 31, 2025 | Mar 30, 2026 | 10-K |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | -$1.83M | Jan 1, 2025 – Dec 31, 2025 | Mar 30, 2026 | 10-K |
| Total assetsAssets | $2.93M | Dec 31, 2025 | Mar 30, 2026 | 10-K |
| Total liabilitiesLiabilities | $1.1M | Dec 31, 2025 | Mar 30, 2026 | 10-K |